Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
July 20, 2009
- Adoair Included in GL for COPD
July 20, 2009
- Treatment with Sprycel Begun in 600 Patients: Bristol-Myers
July 20, 2009
- Flat-Sum System to Be Maintained for High-Priced Drugs
July 20, 2009
- Micombi Can Be Differentiated from Other Combination Drugs: Mr Imahori of Astellas
July 20, 2009
- Fuji Keizai Predicts 4% Increase in OTC Anti-Obesity Drugs in 2009
July 20, 2009
- Higher Dosage Approved for Cravit: Daiichi Sankyo
July 20, 2009
- Sales of Class 1 OTC Drugs Down due to New Marketing System
July 20, 2009
- New Class 1 OTC Drugs Get Off to Flying Start: Taisho
July 20, 2009
- R&D NEWS IN BRIEF
July 20, 2009
- Japan Biotechnology Conference Kicked Off by 20 Biotech Firms
July 20, 2009
- ASCO 2009 Highlight Seminar by the Matson Jack Group
July 20, 2009
- Pfizer Discontinues PIII Trial of Sutent in Metastatic CRC
July 20, 2009
- Chugai Obtains 51% Share in Market for Antibody Pharmaceuticals in Japan
July 13, 2009
- Wyeth Enters into Comprehensive Agreement with NHO for Clinical Trials
July 13, 2009
- Nippon Kayaku: Generics Drive Sales Up to ¥45.77 Bil.
July 13, 2009
- i3 to Embark on CRO Market in Japan in Earnest
July 13, 2009
- ON THE MOVE
July 13, 2009
- Selection of Patients Holds Key to Success of Molecular-Targeted Drugs
July 13, 2009
- BUSINESS NEWS IN BRIEF
July 13, 2009
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…